Chemoprophylactic effect of PD-1/PD-L1 inhibitor treatment on non-melanoma skin cancer development

J Am Acad Dermatol. 2026 Mar;94(3):1017-1019. doi: 10.1016/j.jaad.2025.11.057. Epub 2025 Nov 21.

¹ Department of Dermatology, The Ohio State University Medical Center, Columbus, Ohio.
² The Ohio State University College of Medicine, Columbus, Ohio.
³ Department of Dermatology, Baylor College of Medicine, Houston, Texas.
⁴ Department of Dermatology, Texas Tech University, Lubbock, Texas.
⁵ Department of Internal Medicine, The Ohio State University Medical Center, Columbus, Ohio.
⁶ Department of Dermatology, The Ohio State University Medical Center, Columbus, Ohio. Electronic address: Kathryn.shahwan@osumc.edu.

No abstract available

Keywords: PD-1/PD-L1 inhibitor; chemoprophylaxis; immune checkpoint inhibitor; immunotherapy; non-melanoma skin cancer.